Skip to main content

Rapport Therapeutics, Inc.

corporate_fare Company Profile

Rapport Therapeutics, Inc.

RAPP·NASDAQ·Life Sciences·CIK 0002012593

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The company's foundational science explores neuronal receptor biology, allowing it to identify and target specific neuronal receptor complexes. These complexes are made up of receptor principal subunits and receptor associated proteins (RAPs), which are important for regulating how receptors function and are expressed. Rapport Therapeutics believes its expertise in RAP biology allows it to target previously inaccessible areas and develop neurological and psychiatric drugs that are specific to certain receptor variants and brain regions linked to diseases. This specificity aims to reduce the undesired side effects often seen with most neuroactive drugs. The company is developing a portfolio of precision product candidates based on its RAP technology platform, which originated from its founders' discoveries about RAP function in the brain. This platform aims to overcome limitations of traditional neurology drug discovery. RAP-219 is Rapport Therapeutics' most advanced product candidate. It is an AMPA receptor (AMPAR) negative allosteric modulator (NAM). RAP-219 is designed to achieve neuroanatomical specificity by selectively targeting TARP  8, a RAP associated with neuronal AMPARs. While AMPARs are widely distributed in the central nervous system (CNS), TARP  8 is expressed only in specific regions like the neocortex and mesial temporal lobe, where focal onset seizures (FOS) often begin. TARP  8 has low expression in the hindbrain, a region often linked to adverse drug events. The company believes RAP-219 has the potential for a differentiated profile compared to traditional neuroscience medications.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for RAPP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RAPP spans 8-K, 4, 424B5, FWP.

Recent high-impact activity:

  • Rapport Posts Q3 Loss of $40.2M, Pro Forma Cash of $815.4M and Runway Through 2029
  • Director Healy Buys $20.4M of Rapport Stock at $21.00 Offering Price
  • Rapport Closes ~$355M Raise: $175M Stock, $172.5M Convertible Notes, $30M PIPE
  • Rapport Finalizes $21.00 Offering: 8.3M Shares Plus Warrants, ~$215.7M Net
  • Rapport Prices $175M Stock, $150M Convertible Notes and $30M Private Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$111.48M
Diluted EPS
-$2.86
Op. Cash Flow
-$87.47M
Free Cash Flow
-$88.09M
Operating Income
-$125.1M
Cash & Equivalents
$52.65M
Debt / Equity
0.00×
Shares Outstanding
47.77M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-099360

Short Interest & Short Volume

1.79 days to cover

FINRA reported short interest of 3,956,396 shares in RAPP as of the October 30, 2026 settlement, a 29.7% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 55.7% of RAPP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,956,396 shares as of October 30, 2026
Change vs prior period▲ 29.7%
Days to cover1.79 at avg daily volume of 2,214,106
Daily short volume (FINRA facilities)55.7% of 133,221 shares on November 20, 2026
5-day average short volume66.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RAPP, detected from its recent SEC filings · based on capital-structure filings through 2026-10-30.

1 recent capital raise

Equity Offering Priced at $21.00 · Private Placement Adds ~$30M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$23.16
52-week range · as of 2026-11-04 $22.06 – $52.93
Market cap
$1.37B
Volume
437.7K (0.4× avg)
3-mo avg 1.2M
Live data · 2026-11-22 09:27 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RAPP - Latest Insights

RAPP
Nov 04, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.48
Real-time Price: $23.16 info
Change: -$2.32 (-9%) info
Market Cap: $1.373B info
RAPP
Oct 30, 2026, 7:32 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $23.16 info
Change: -$1.40 (-6%) info
Market Cap: $1.373B info
RAPP
Oct 30, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.56
Real-time Price: $23.16 info
Change: -$2.40 (-9%) info
Market Cap: $1.373B info
RAPP
Oct 30, 2026, 7:04 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.55
Real-time Price: $23.16 info
Change: +$0.610 (+3%) info
Market Cap: $1.373B info
RAPP
Oct 28, 2026, 6:18 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $21.80
Real-time Price: $23.16 info
Change: +$1.36 (+6%) info
Market Cap: $1.373B info
RAPP
Oct 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $22.31
Real-time Price: $23.16 info
Change: +$0.850 (+4%) info
Market Cap: $1.373B info
RAPP
Oct 27, 2026, 9:30 PM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $22.00
Real-time Price: $23.16 info
Change: +$1.16 (+5%) info
Market Cap: $1.373B info
RAPP
Oct 27, 2026, 4:52 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $23.16 info
Change: +$0.660 (+3%) info
Market Cap: $1.373B info
RAPP
Oct 27, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $27.94
Real-time Price: $23.16 info
Change: -$4.78 (-17%) info
Market Cap: $1.373B info
RAPP
Oct 20, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $30.92
Real-time Price: $23.16 info
Change: -$7.76 (-25%) info
Market Cap: $1.373B info
RAPP
Oct 20, 2026, 6:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $35.50
Real-time Price: $23.16 info
Change: -$12.34 (-35%) info
Market Cap: $1.373B info
RAPP
Aug 05, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $40.51
Real-time Price: $23.16 info
Change: -$17.35 (-43%) info
Market Cap: $1.373B info
RAPP
Aug 05, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.51
Real-time Price: $23.16 info
Change: -$17.35 (-43%) info
Market Cap: $1.373B info
RAPP
May 27, 2026, 9:16 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $39.71
Real-time Price: $23.16 info
Change: -$16.55 (-42%) info
Market Cap: $1.373B info
RAPP
May 07, 2026, 4:44 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $39.93
Real-time Price: $23.16 info
Change: -$16.77 (-42%) info
Market Cap: $1.373B info
RAPP
May 07, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $37.06
Real-time Price: $23.16 info
Change: -$13.90 (-38%) info
Market Cap: $1.373B info
RAPP
May 07, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $37.06
Real-time Price: $23.16 info
Change: -$13.90 (-38%) info
Market Cap: $1.373B info
RAPP
Apr 21, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.95
Real-time Price: $23.16 info
Change: -$13.79 (-37%) info
Market Cap: $1.373B info
RAPP
Apr 21, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $36.95
Real-time Price: $23.16 info
Change: -$13.79 (-37%) info
Market Cap: $1.373B info
RAPP
Apr 17, 2026, 4:37 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $39.71
Real-time Price: $23.16 info
Change: -$16.55 (-42%) info
Market Cap: $1.373B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets